777pub open now philippines
Traffic citations against Dolphins' Tyreek Hill dismissed after officers no-show at hearingENID, Okla. — Gov. Kevin Stitt says Oklahoma will be prepared to start deporting undocumented housed in state prisons as soon as Donald Trump is sworn in as president. As part of his announcement in a news release issued Nov. 15, 2024, Stitt named Public Safety Commissioner Tim Tipton to lead the planning efforts of Operation Guardian. What affect Stitt’s plan has on Northwest Oklahoma law enforcement remains unknown. Daylen Rivers, Garfield County Detention Facility administrator, said the jail usually has few undocumented people in custody. “I’d say we have only about one or two illegal immigrants a month or less,” Rivers said. Rivers said the way the process works for his facility is that the jail processes inmates who did not have legal identification, then calls Immigration and Custom Enforcement. “They would go to court to face their charges, then ICE would pick them up pretty quickly,” Rivers said. “Then they would usually take them to Tulsa.” Garfield County Sheriff Corey Rink said his office picks up people who committed a crime and their race really didn’t factor into the situation. “If they were illegal, most of the time they were getting caught on driving violations,” Rink said. “It would be things like not having a license or it not being their car.” Cass Rains, a spokesman for Enid Police Department, had the same answer. “It would take some time to do research on the numbers,” he said. Stitt said in his news release that he didn’t want the state to pay for what he described as the costs of the Biden administration’s “open border policies.” “As law and order returns to the White House, Oklahoma will lead the charge with a comprehensive plan to deport those who have committed crimes in Oklahoma while in the country illegally,” Stitt said in the announcement. “I am still committed to finding ways to pursue state-based workforce visas for those who want to pursue the American dream, but we will not tolerate criminal activity in our state.” Stitt said he believes Oklahoma’s efforts could serve as a model for other states. According to the governor, Oklahoma Department of Corrections houses 526 undocumented people. Locally, though, few remain in jail for long. “We move them on pretty quickly after they have faced their charges,” Rivers said. Click for the latest, full-access Enid News & Eagle headlines | Text Alerts | app downloads | news and sports emails .
Investing.com stocks of the weekAP Business SummaryBrief at 12:58 p.m. EST
None
Social media ban slammed amid push to bring it forward
Funeral for Jimmy Carter: What happens when a president dies?
Green Bay Packers quarterback Jordan Love played interception-free football for the first time this season during a home rout of the San Francisco 49ers on Sunday. The Packers' Thanksgiving night home clash with the Miami Dolphins offers a chance to be equally efficient. Just don't expect Love to scale back his approach in the meeting of playoff contenders. ADVERTISEMENT "I definitely am a guy who always wants those big plays, want to put that pressure on the defense and take some of those shots," Love said. Love threw for a season-low 163 yards on 13-of-23 passing to go with two touchdowns against the 49ers. Still, with Josh Jacobs (26 carries, 106 yards, three touchdowns) wreaking havoc in the running game, Love found opportunities to strike a balance. "Those are the lessons that I had to learn last year and I'll continue to learn: just when the right time (is) to take those shots," he said. "If guys get a step or we're in the right coverage versus just finding those completions. Because these check-downs and just finding those completions turn into big plays, as well, sometimes." Green Bay (8-3) is third in the rugged NFC North but holds a two-game lead in the loss column for the No. 6 seed in the conference playoff race. Winners of three straight, the Dolphins (5-6) are 1 1/2 games behind the Denver Broncos for the seventh seed in the AFC. "I think this is an awesome opportunity," Dolphins quarterback Tua Tagovailoa said. "Being able to play Thursday night football, prime time on Thanksgiving." Tagovailoa continues to surge since returning from injured reserve in Week 8. With four touchdown passes during a 34-15 home win against the New England Patriots on Sunday, he has 11 TDs through the air against just one interception in his five games back. ADVERTISEMENT Tagovailoa dismissed the notion that chilly temperatures in Green Bay on Thursday could be enough to cool him. The Hawaiian-born signal-caller is 0-7 when the temperature is 40 degrees or lower. "To me, it's just a mindset," he said. "That's really all there is." Added Miami defensive coordinator Anthony Weaver: "I've never lost a game and thought, 'Guys, it was too cold outside.'" Miami boasts a versatile set of playmakers for Green Bay to defend. Running back De'Von Achane also is active in the passing game, as he made two touchdown receptions against New England. Among the Dolphins' receivers, wideouts Tyreek Hill and Jaylen Waddle and tight end Jonnu Smith each have at least 41 receptions and 535 yards. The three have combined for nine TDs. Green Bay is hoping for another jolt from second-year linebacker Lukas Van Ness, whose strip-sack against the 49ers was the big play he said he needed for his confidence. It led to Jacobs' third TD. "I told myself I'm going to get off the ball, use my God-given abilities and just get in the backfield and make a play," Van Ness said. "So I think that's what I've wanted to do all year. I just need to continue that." ADVERTISEMENT The Dolphins said Wednesday that Hill, who has dealt with wrist and personal issues this week, does not have an injury designation and will play against the Packers. Cornerback Kendall Fuller (concussion) and linebackers Tyus Bowser (knee/calf) and Anthony Walker Jr. (hamstring) have been ruled out, and offensive tackle Terron Armstead (knee) is questionable. The Packers ruled out wide receiver Romeo Doubs (concussion), cornerback Jaire Alexander (knee) and linebacker Edgerrin Cooper (hamstring) after they did not practice all week. Tight end John FitzPatrick (back), linebacker Isaiah McDuffie (ankle) and offensive lineman Josh Myers (pectoral) were listed as questionable. Miami leads the all-time series 10-6, but Green Bay has won five of the past six matchups. The teams' most recent meeting also came on a holiday, with the visiting Packers prevailing 26-20 on Christmas Day 2022. Green Bay won each of its previous November home games against Miami, in 2002 and 2018. ______________________________________________________ This story was written by one of our partner news agencies. Forum Communications Company uses content from agencies such as Reuters, Kaiser Health News, Tribune News Service and others to provide a wider range of news to our readers. Learn more about the news services FCC uses here .The accusation that President Bola Tinubu favours his ethnic Yoruba to dominate the Nigerian National Petroleum Corporation Limited (NNPCL’s) hierarchy and the financial sector of the nation’s economy is baseless, a former presidential aide, Mr Reno Omokri, has said. In a statement on Sunday, the former presidential aide said the accusation contradicts the facts, which show that the president has been even-handed in his choice of appointments. In an article titled “Tinubu’s Buharisation of the NNPC,” published last week, an academic, Prof Farouk Kperogi, accused President Tinubu of appointing “Yoruba people” to significant positions at the NNPC. He added that the concentration of Yoruba figures in critical economic roles, including the minister of finance and the governor of the Central Bank of Nigeria (CBN), represented “state-sanctioned ethnocentric domination of a critical segment of national life.” But a former governor of Kaduna State, Mr Nasir el-Rufai, responded to Kperogi’s claim on his X handle, admonishing, “Two wrongs do not make a right. Sensible inclusion always trumps arrogant exclusion!” However, the Chief Corporate Communications Officer of the NNPC Ltd., Olufemi Soneye, addressed concerns raised in Kperogi’s article in a weekend statement, explaining that the NNPC’s leadership structure was guided by business requirements, expertise, and merit rather than ethnicity, tribe, religion, or political affiliation. He said the NNPCL prided itself on being a professional organisation with a diverse leadership team that includes individuals from various parts of the world. On Sunday, Omokri weighed in on the matter and said el-Rufai and Kperogi were mischievously misrepresenting facts. “Let us consider the facts,” he said, adding, “Look at the breakdown of the current management of the NNPCL: Chief Pius Akinyelure: Non-Executive Board Chairman-Southwest; Mallam Mele Kolo Kyari: Group Chief Executive Officer-Northeast; Adedapo Segun: Chief Financial Officer-Southwest; Mr Ledum Mitee: Non-Executive Director-South-South; Mr Musa Tumsa: Non-Executive Director-Northeast; Mr Ghali Muhammad: Non-Executive Director-Northcentral; Prof Mustapha Aliyu: Non-Executive Director-Northwest; Mr. David Ogbodo: Non-Executive Director-Southeast; and Ms. Eunice Thomas: Non-Executive Director-South-South. He said from the record that only two company board members were from the Southwest, explaining that none of the top management of the supervisory agencies was from the president’s region. He pointed out that the Minister of State for Petroleum Resources (Oil), Senator Heineken Lokpobori, and Minister of State for Petroleum Resources (Gas), Mr Ekperikpe Ekpo, were from the South-South, while the Permanent Secretary, Federal Ministry of Petroleum Resources, Mr Nicholas Agbo Ella, was -North-Central. “From the above, how can anybody honestly project to the Nigerian people that President Tinubu is Yorubacentric in his appointments at the NNPCL? It beggars belief,” Omokri said. His words, “If there is any dominance at all, then that hegemony favours the South-South, which is the most represented on the board and cabinet-level with authority over NNPCL. Then you have the Northwest, Northeast, and North-Central. “Now, even if you want to go to the ridiculous extent of scrutinising those in the lower cadre of the NNPCL, you will find that, except possibly two positions, all of those posts were filled by former President Muhammadu Buhari. “Therefore, to say that a Yoruba heads every consequential agency in finance in Nigeria is not only without basis but also capable of causing the type of market ripples that negatively affect the All-Share Index of the Nigerian Stock Exchange. “When you mention finance, you use a broad brush that includes revenue-generating agencies. And the highest revenue-generating agencies in Nigeria are not the Central Bank of Nigeria or the Ministry of Finance.”
By HALELUYA HADERO, Associated Press President-elect Donald Trump asked the Supreme Court on Friday to pause the potential TikTok ban from going into effect until his administration can pursue a “political resolution” to the issue. The request came as TikTok and the Biden administration filed opposing briefs to the court, in which the company argued the court should strike down a law that could ban the platform by Jan. 19 while the government emphasized its position that the statute is needed to eliminate a national security risk. “President Trump takes no position on the underlying merits of this dispute. Instead, he respectfully requests that the Court consider staying the Act’s deadline for divestment of January 19, 2025, while it considers the merits of this case,” said Trump’s amicus brief, which supported neither party in the case. The filings come ahead of oral arguments scheduled for Jan. 10 on whether the law, which requires TikTok to divest from its China-based parent company or face a ban, unlawfully restricts speech in violation of the First Amendment. Earlier this month, a panel of three federal judges on the U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld the statute , leading TikTok to appeal the case to the Supreme Court. The brief from Trump said he opposes banning TikTok at this junction and “seeks the ability to resolve the issues at hand through political means once he takes office.”DEIR AL-BALAH, Gaza Strip (AP) — Israeli troops stormed one of the last hospitals operating in northern Gaza on Friday, forcing many staff and patients outside to strip in winter weather , the territory’s health ministry said. The army denied claims it had entered or set fire to the complex and accused Hamas of using the facility for cover. Kamal Adwan Hospital has been hit multiple times over the past three months by Israeli troops waging an offensive against Hamas fighters in surrounding neighborhoods, according to staff. The ministry said a strike on the hospital a day earlier killed five medical staff. Israel's military said it was conducting operations against Hamas infrastructure and militants in the area and had ordered people out of the hospital, but said it had not entered the complex as of Friday night. It repeated claims that Hamas militants operate inside Kamal Adwan but provided no evidence. Hospital officials have denied that. The Health Ministry said troops forced medical personnel and patients to assemble in the yard and remove their clothes. Some were led to an unknown location, while some patients were sent to the nearby Indonesian Hospital, which was knocked out of operation after an Israel raid this week. Israeli troops during raids frequently carry out mass detentions, stripping men to their underwear for questioning in what the military says is a security measure as they search for Hamas fighters. The Associated Press doesn’t have access to Kamal Adwan, but armed plainclothes members of the Hamas-led police forces have been seen in other hospitals, maintaining security but also controlling access to parts of the facilities. The Health Ministry said Israeli troops also set fires in several parts of Kamal Adwan, including the lab and surgery department. It said 25 patients and 60 health workers remained in the hospital. The account could not be independently confirmed, and attempts to reach hospital staff were unsuccessful. “Fire is ablaze everywhere in the hospital,” an unidentified staff member said in an audio message posted on social media accounts of hospital director Hossam Abu Safiya. The staffer said some evacuated patients had been unhooked from oxygen. “There are currently patients who could die at any moment,” she said. Lt. Col. Nadav Shoshani, an Israeli military spokesman, denied the accusations. “While IDF troops were not in the hospital, a small fire broke out in an empty building inside the hospital that is under control,” he said Friday night. He said a preliminary investigation found “no connection” between military activity and the fire. The Israeli military heavily restricts the movements of Palestinians in Gaza and has barred foreign journalists from entering the territory throughout the war, making it difficult to verify information. “These actions put the lives of all of these people in even more danger than what they faced before,” U.N. spokesperson Stephanie Tremblay told journalists, and noted colleagues' reports of “significant damage” to the hospital. It should be protected as international law requires, she added. Since October, Israel’s offensive has virtually sealed off the northern Gaza areas of Jabaliya, Beit Hanoun and Beit Lahiya and leveled large parts of them. Tens of thousands of Palestinians were forced out but thousands are believed to remain in the area, where Kamal Adwan and two other hospitals are located. Troops raided Kamal Adwan in October, and on Tuesday troops stormed and evacuated the Indonesian Hospital. The area has been cut off from food and other aid for months , raising fears of famine . The United Nations says Israeli troops allowed just four humanitarian deliveries to the area from Dec. 1 to Dec. 23. The Israeli rights group Physicians for Human Rights-Israel this week petitioned Israel’s High Court of Justice, seeking a halt to military attacks on Kamal Adwan. It warned that forcibly evacuating the hospital would “abandon thousands of residents in northern Gaza.” Before the latest deaths Thursday, the group documented five other staffers killed by Israeli fire since October. Israel launched its campaign in Gaza vowing to destroy Hamas after the group’s Oct. 7, 2023, attack on southern Israel in which militants killed around 1,200 people and abducted some 250 others. Around 100 Israelis remain captive in Gaza, around a third believed to be dead. Israel’s nearly 15-month-old campaign of bombardment and offensives has devastated the territory’s health sector. A year ago, it carried out raids on hospitals in northern Gaza, including Kamal Adwan, Indonesian and al-Awda Hospital, saying they served as bases for Hamas, though it presented little evidence. Israel’s campaign has killed more than 45,400 Palestinians, more than half women and children, and wounded more than 108,000 others, according to the Health Ministry. Its count does not distinguish between civilians and combatants. More than 90% of Gaza’s 2.3 million Palestinians have been driven from their homes, most now sheltering in sprawling tent camps in south and central Gaza. Children and adults, many barefoot, huddled Friday on the cold sand in tents whose plastic and cloth sheets whipped in the wind. Overnight temperatures can dip into the 40s Fahrenheit (below 10 Celsius), and sea spray from the Mediterranean can dampen tents just steps away. "I swear to God, their mother and I cover ourselves with one blanket and we cover (their five children) with three blankets that we got from neighbors. Sea waters drowned everything that was ours,” said Muhammad al-Sous, displaced from Beit Lahiya in the north. The children collect plastic bottles to make fires, and pile under the blankets when their only set of clothes is washed and dried in the wind. At least three babies in Gaza have died from exposure to cold in recent days , doctors there have said, and the Health Ministry said an adult — a nurse who worked at the European Hospital — also died this week. Khaled and Keath reported from Cairo. Associated Press writer Edith M. Lederer at the United Narions contributed to this report.The Internet's Best Boyfriends of 2024, Ranked
Android tablets have been mostly a miss for most users, at least in the U.S. The iPad has been dominating the tablet scene, but there is a space for quality budget tablets and the Lenovo Tab Plus (2024) is probably the best budget Android tablet you can get. Samsung makes an excellent premium Android tablet, but the budget category doesn’t belong to them. The Lenovo Tab Plus starts at $200, and you can even get it cheaper with sales, and it’s better than the price tag implies. Estimated reading time: 9 minutes I have almost given up on Android tablets, but the Lenovo Tab Plus does give me hope. The iPad remains king, but it’s also expensive. Let’s get into the full review of the Lenovo Tab Plus, 2024 version. The Quick Take I’m not a huge fan of Android tablets, I’ve made that known for years. But there are a handful of tablets that are pretty decent. I was not expecting the Lenovo Tab Plus to be one of them. I think what really made this tablet stand out are the speakers. The sound on this tablet makes it an excellent content consumption device, so watching movies on it is very enjoyable. Here’s what I liked and didn’t like. What I liked Solid build quality for a budget tablet Materials used are far above a budget tablet, shocking The display is bright and colorful The speakers are probably the best speakers on any budget tablet, almost iPad level Great battery life The built-in stand is spectacular What I didn’t like The cameras are just OK, but really, tablet photos are just weird Performance is fine, but expect heavy gaming will lag I would recommend this tablet for its sound quality and excellence for movie watching. Perfect for kids and people who just want to watch content. Specifications The Lenovo Tab Plus has the following features and specifications: Processor: MediaTek® Helio G99 (8C, 2x A76 @2.20GHz + 6x A55 @2.00GHz) Operating System Operating System: Android 14 Upgradable until Android 16 Security patches until January 2028 Memory: 8 GB Storage: Up to 256GB integrated storage Supports up to 1TB expandable storage Battery: 8600mAh 45W fast charging Audio: 8x JBL speakers tuned with Dolby Atmos Camera: Front: 8MP, fixed focus Rear: 8MP, autofocus Connectivity: Ports/Slots: USB-C 2.0 (charging + audio) Headphone/mic combo MicroSD slot Wireless Wi-Fi 5 802.11AC (1 x 1) Bluetooth® 5.2 Display: 11.5′′ 2K (2000 X 1200) TFT LCD, 400 nits, 90Hz refresh rate, touchscreen, TUV certified Dimensions (H x W x D): 174.25mm x 268.3mm x 7.77mm, with speaker bump 13.58mm / 6.86′′ x 10.56′′ x 0.31′′ Weight: Starting at .65kg / 1.43lbs Pen: Lenovo Tab Pen Plus (optional) Color: Luna Grey Security: Security patches until January 2028 Preloaded Software: Entertainment Space Google TV Lenovo Freestyle Lenovo Vantage Music MyScript Calculator 2 Nebo Standby Mode YouTube WPS Office What’s In The Box Lenovo Tab Plus USB-C 2.0 Charging Cable 45W Charging Adapter MicroSD Tray Pin Quick Start Guide Safety & Warranty Guide Design Holy cow! The Lenovo Tab Plus design is truly impressive for its sub two hundred dollar price point. You get yourself a full aluminum build with really high-end materials being used. I was expecting a plastic tablet, and that is not what you get here. The front is pretty plain, just the display with a hole punch camera. The bottom is equally uneventful. The top edge houses the volume rocker, SD Card tray, and mics. The right edge houses the USB-C charging port, one set of the JBL speakers, and some venting. The left edge houses the AUX port, the other set of JBL speakers, and the power button. Both the left, and right edges have some really nice accenting around the speakers that give the design a premium look. The back houses the camera and an excellent kickstand that works really well and is sturdy and versatile. So far, very impressed with this design and build. The Lenovo Tab Plus has a solid build, but it’s not too heavy at less than a pound a half. That weight goes up slightly if you use the included cover. The cover is just okay, it does a good job for protection, but I didn’t like the look of it. But fine for keeping the tablet protected. Overall, the design is actually very nice for a budget tablet. I was shocked at how nice the materials were and how good-looking the Lenovo Tab Plus is overall. Display A brief reminder about the Lenovo Tab Plus, this is a budget tablet, people. Not all aspects of this thing are going to compete with tablets in a much higher price category. That said, the display housed in this chassis is an 11.5′′ 2K (2000 X 1200) TFT LCD, 400 nits, 90Hz refresh rate, touchscreen, TUV certified display. It’s a good resolution with a decent refresh rate. Brightness is also good, but I will say there is some glare and off axis viewing can sometimes be an issue. Not a dealbreaker because the price point supports this. Colors are pretty neutral, this is not an AMOLED display so no over saturation and colors are less punchy. Blacks are fine, if you’re paying attention, you can see they are not as deep as an AMOLED, but again, the price point and display tech support the price. The Whites are clean though and the text is crisp. The 90Hz refresh rate gives you smooth scrolling and a pleasant use with light gaming. Overall, this is an excellent display for a budget tablet. It’s not as punchy as an AMOLED, but it’s really a great display for what you pay. Android Software The Lenovo Tab Plus comes with Android 14, but Lenovo claims they will give it updates to Android 16. So that is an excellent thing. This means you spend, not a lot of money, on a tablet that will have a few years of OS updates. There is some bloatware installed on this tablet, which sucks, but you can uninstall it. I know companies pay for having their apps installed on these types of tablets, and it helps reduce costs. But it is still annoying. Things like TikTok, Block Blast, Block Puzzle Adventure, Booking dot com, and other apps are all preinstalled. Normally, I would be very upset by this, but given the price of this tablet, it’s tolerable. And you can delete these apps. Overall, the software is great on the OS side. The bloatware is annoying. Performance and Camera Don’t expect massive gaming performance from the Lenovo Tab Plus. This is not a gaming tablet. But you can play some games on it. I think even heavy games are doable for a short time, but serious gamers should look elsewhere. For everyday performance, like web browsing, email, social media, and watching movies, it works very well. The MediaTek® Helio G99 paired with 8GB of RAM is enough for most normal users and should hold up well. As for the cameras. I roped them in with performance because they are just okay. Not anything special, but I don’t think many people take serious photos with tablets. The front facing camera works fine for video calls and whatnot. The rear camera is just okay. But again, the price here meets the hardware. Speakers The speakers are where the Lenovo Tab Plus shines. These are impressive and excellent speakers that are tuned by JBL. Usually, speakers on tablets are pretty bad. But the Lenovo Tab Plus gives you EIGHT speakers which provide EXCELLENT sound. I am serious when I say that these are even better than some higher end Android tablet speakers. They are pretty damn close to the iPad’s speakers, and that is saying a lot. The bottom end is REALLY good on them, and watching movies is one of the most enjoyable activities to do on this tablet. Lenovo really knocked it out of the park on these speakers. They, alone, are worth the price of this tablet. Battery Life The 8,600mAh battery is massive, and you get a 45W fast charger in the box. This tablet can last for days, depending on what you’re doing. I didn’t stress test it, but it lasted me for three or four days with light use and YouTube watching. This is an excellent battery. Price/Value There’s not much more to say about the Lenovo Tab Plus. Is it perfect? Nope. It is not perfect. But its price point is forgiving. I can tolerate many of its downfalls because its good points are greater. I would recommend this tablet for anyone just wanting a content consumption device that has fantastic sound. In some of our articles and especially in our reviews, you will find Amazon or other affiliate links. As Amazon Associates, we earn from qualifying purchases. Any other purchases you make through these links often result in a small amount being earned for the site and/or our writers. Techaeris often covers brand press releases. Doing this does not constitute an endorsement of any product or service by Techaeris. We provide the press release information for our audience to be informed and make their own decision on a purchase or not. Only our reviews are an endorsement or lack thereof. For more information, you can read our full disclaimer .
outboundIQ Achieves Certified Implementation Partner (CIP) Status with Five9CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $
Mid-American Conference football goes all in on November weeknights for the TV viewers
Stock market today: Wall Street rises at the start of a holiday-shortened week
WEST PALM BEACH, Fla. (AP) — An online spat between factions of Donald Trump’s supporters over immigration and the tech industry has thrown internal divisions in his political movement into public display, previewing the fissures and contradictory views his coalition could bring to the White House. The rift laid bare the tensions between the newest flank of Trump’s movement — wealthy members of the tech world including billionaire Elon Musk and fellow entrepreneur Vivek Ramaswamy and their call for more highly skilled workers in their industry — and people in Trump’s Make America Great Again base who championed his hardline immigration policies. The debate touched off this week when Laura Loomer, a right-wing provocateur with a history of racist and conspiratorial comments, criticized Trump’s selection of Sriram Krishnan as an adviser on artificial intelligence policy in his coming administration. Krishnan favors the ability to bring more skilled immigrants into the U.S. Loomer declared the stance to be “not America First policy” and said the tech executives who have aligned themselves with Trump were doing so to enrich themselves. Much of the debate played out on the social media network X, which Musk owns. Loomer’s comments sparked a back-and-forth with venture capitalist and former PayPal executive David Sacks, whom Trump has tapped to be the “White House A.I. & Crypto Czar.” Musk and Ramaswamy, whom Trump has tasked with finding ways to cut the federal government, weighed in, defending the tech industry’s need to bring in foreign workers. It bloomed into a larger debate with more figures from the hard-right weighing in about the need to hire U.S. workers, whether values in American culture can produce the best engineers, free speech on the internet, the newfound influence tech figures have in Trump’s world and what his political movement stands for. Trump has not yet weighed in on the rift. His presidential transition team did not respond to questions about positions on visas for highly skilled workers or the debate between his supporters online. Instead, his team instead sent a link to a post on X by longtime adviser and immigration hard-liner Stephen Miller that was a transcript of a speech Trump gave in 2020 at Mount Rushmore in which he praised figures and moments from American history. Musk, the world’s richest man who has grown remarkably close to the president-elect, was a central figure in the debate, not only for his stature in Trump’s movement but his stance on the tech industry’s hiring of foreign workers. Technology companies say H-1B visas for skilled workers, used by software engineers and others in the tech industry, are critical for hard-to-fill positions. But critics have said they undercut U.S. citizens who could take those jobs. Some on the right have called for the program to be eliminated, not expanded. Born in South Africa, Musk was once on an a H-1B visa himself and defended the industry’s need to bring in foreign workers. “There is a permanent shortage of excellent engineering talent,” he said in a post. “It is the fundamental limiting factor in Silicon Valley.” Trump’s own positions over the years have reflected the divide in his movement. His tough immigration policies, including his pledge for a mass deportation, were central to his winning presidential campaign. He has focused on immigrants who come into the U.S. illegally but he has also sought curbs on legal immigration, including family-based visas. As a presidential candidate in 2016, Trump called the H-1B visa program “very bad” and “unfair” for U.S. workers. After he became president, Trump in 2017 issued a “Buy American and Hire American” executive order, which directed Cabinet members to suggest changes to ensure H-1B visas were awarded to the highest-paid or most-skilled applicants to protect American workers. Trump’s businesses, however, have hired foreign workers, including waiters and cooks at his Mar-a-Lago club, and his social media company behind his Truth Social app has used the the H-1B program for highly skilled workers. During his 2024 campaign for president, as he made immigration his signature issue, Trump said immigrants in the country illegally are “poisoning the blood of our country” and promised to carry out the largest deportation operation in U.S. history. But in a sharp departure from his usual alarmist message around immigration generally, Trump told a podcast this year that he wants to give automatic green cards to foreign students who graduate from U.S. colleges. “I think you should get automatically, as part of your diploma, a green card to be able to stay in this country,” he told the “All-In” podcast with people from the venture capital and technology world. Those comments came on the cusp of Trump’s budding alliance with tech industry figures, but he did not make the idea a regular part of his campaign message or detail any plans to pursue such changes.
Rep. Chip Roy (R-TX) on Friday said Americans would celebrate cuts to the federal budget by the so-called Department of Government Efficiency, or DOGE – including a crackdown on food stamps and Medicaid. The comments came Friday during Roy’s appearance on CNBC’s “ Squawk Box ,” where he called on “the DOGE guys” – billionaires Elon Musk and Vivek Ramaswamy – to identify non-defense discretionary spending that can be slashed . “What do you think they’re really going to be able to go after?” host Andrew Ross Sorkin asked. “If we were to go through and just put in restraints on the use of food stamps to feed our people sugar, for example...we can save hundreds of billions of dollars,” Roy, a conservative member of the House Freedom Caucus, told the host. He added other examples such as repealing the Inflation Reduction Act and a “return to non-defense to pre-Covid era explosion in spending” to also help reduce spending. ALSO READ: 'That's one take': CNN host gives 'side eye' to GOP strategist's analysis of MAGA clash “We can do a lot of savings right out of the gate to reverse the Biden damage, get the economy going, reduce regulations – but not touch benefits that our seniors rely on – yes, we need to address Medicare and Social Security in the long haul, no question, but right now we should reverse Biden damage, get spending restraint on Medicaid, reforms that need to be put in place [and] tax policy that matches all of that.” The MAGA lawmaker added that members of Congress also have to “do our job to constrain the bureaucracy cutting non-defense discretionary." "That would only be a 13 percent cut, you and I can find 13 percent of waste, and I think the DOGE guys too and that would be fiscally responsible and the American people would cheer President Trump and Republicans if we do that.” Roy said he thinks Musk and Ramaswamy will have “significant influence” in what cuts Congress ultimately makes next year. “They’re identifying a lot of spending waste that I think they can use their pulpit and I think they can broadcast that and shine a light on it,” Roy said.CLEVELAND (AP) — Germain Ifedi became the fourth left tackle to start this season for the Cleveland Browns, lining up Thursday night against the AFC North-leading Pittsburgh Steelers. Ifedi moved up the depth chart and into the lineup after starter Dawand Jones broke his left leg last week at New Orleans and had surgery. He'll be responsible for blocking quarterback Jameis Winston's blindside. Jedrick Wills Jr., who had lost his starting job to Jones, figured to start against the Steelers (8-2), but was ruled out Wednesday with a knee injury that has bothered him for weeks. A first-round pick in 2020, Wills recently caused a stir by saying he made a “business decision” to sit out a game on Oct. 27 against Baltimore because of his knee. Coach Kevin Stefanski said Wills used a “poor choice of words.” James Hudson started Cleveland's first two games at left tackle while the Browns (2-8) waited for Wills to recover from knee surgery in December. The first-place Steelers were without outside linebacker/edge rusher Alex Highsmith, who missed his second straight game with an ankle injury. AP NFL: https://apnews.com/hub/nfl